Fate Therapeutics (Fate Therapeutics) EBIT : $-212.99 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics EBIT?

Fate Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-51.07 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-212.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fate Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -112.36%. Fate Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -131.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fate Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -150.01%.

Fate Therapeutics EBIT Historical Data

The historical data trend for Fate Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics EBIT Chart

Fate Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-96.40

-128.09

-216.99

-308.39

-190.51

Fate Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-28.59	-62.57	-51.28	-48.08	-51.07

Competitive Comparison of Fate Therapeutics's EBIT

For the Biotechnology subindustry, Fate Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fate Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's EV-to-EBIT falls into.

Fate Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-212.99 Mil.

Fate Therapeutics (NAS:FATE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fate Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-204.272 * ( 1 - 0% )	/	( (181.538	+	182.078)	/ 2 )
=	-204.272	/	181.808
=	-112.36 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	506.217	-	32.233	-	( 315.175	-	max(0, 39.094	-	331.54	+	315.175	))
=	181.538

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	569.892	-	38.808	-	( 383.544	-	max(0, 45.369	-	394.375	+	383.544	))
=	182.078

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Fate Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-204.272	/	( ( (158.511 + max(-16.553, 0))	+	(152.736 + max(-28.136, 0)) )	/	2 )
=	-204.272	/	( ( 158.511	+	152.736 )	/	2 )
=	-204.272	/	155.6235
=	-131.26 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.826	+	0	+	14.539)	-	(32.233	+	0.685	+	0)
=	-16.553

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.858	+	0	+	9.973)	-	(38.808	+	0.159	+	0)
=	-28.136

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fate Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-212.987	/	141.984
	=	-150.01 %

Fate Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Fate Therapeutics (Fate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

F6T:Germany F6T:Germany

Address

12278 Scripps Summit Drive, San Diego, CA, USA, 92131

Website

https://www.fatetherapeutics.com

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Executives

J Scott Wolchko	director, officer: President and CEO	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dulac Edward J Iii	officer: Chief Financial Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Bahram Valamehr	officer: Chief Development Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl	officer: See Remarks	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Brian T. Powl	officer: Chief Commercial Officer	C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu	officer: See Remarks	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein	director
Mark Plavsic	officer: Chief Technical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein	director